Pneumotox » Drug » Adalimumab

Adalimumab

3

Last update : 17/03/2014

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.b Pneumonitis (ILD)

1

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

1

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.g Pulmonary fibrosis

1

I.m ILD with a granulomatous component

1

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

1

I.z An area or areas of consolidation

1

II.b ARDS - Acute lung injury

1

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1

III.d Alveolar hemorrhage, diffuse (ANCA-positive/-related)

1

IV.a Bronchospasm - Wheezing - Asthma

1

V.d Pleural/pericardial effusion, ANA positive (DI lupus)

1

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

1

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

1

X.b Antiphospholipid antibodies w/wo the APL syndrome

1

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

1

X.j Myopathy-Myositis-Polymyositis (see also under Xba)

1

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

1

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

1

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XVI.k Imaging: An area or areas of consolidation

1

XVII.a Respiratory tract infection incl. pneumonia

1

XVII.b Opportunistic pulmonary/systemic infections

2

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

-

XVII.e Pneumocystis jiroveci pneumonia

1

XVII.f Tuberculosis, miliary

1

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

1

XVII.z Histoplamosis (reactivation)

1

XVII.aa Coccidioidomycosis

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist